Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Fig. 3

Overview of MAPK/PI3K signaling pathway and mechanisms of resistance to KRAS inhibitors. a Schematic representation of KRAS cycling and signaling pathway. b Mechanisms of resistance to KRAS inhibitors. Acquired mutations concerning the drug-binding sites and feedback activation of KRAS upstream and downstream signaling pathways favor drug resistance to KRAS mutant inhibitors

Back to article page